Blueprint Medicines
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $128,184 | $138,157 | $96,116 | $71,957 |
Gross Profit | 126,252 | 126,947 | 88,115 | 70,166 |
EBITDA | -33,374 | -29,475 | -74,013 | -103,579 |
EBIT | -37,237 | -33,092 | -78,823 | -105,110 |
Net Income | -56,276 | -49,994 | 89,136 | -110,918 |
Net Change In Cash | 128,184 | 138,157 | 96,116 | 71,957 |
Free Cash Flow | -13,662 | -50,641 | -102,617 | -83,601 |
Cash | 89,356 | 54,771 | 113,326 | 71,286 |
Basic Shares | 63,381 | 62,854 | 63,802 | 60,890 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $249,380 | $204,036 | $180,080 | $793,735 |
Gross Profit | 236,584 | 186,223 | 162,146 | 793,310 |
EBITDA | -474,612 | -515,415 | -628,299 | 308,707 |
EBIT | -486,277 | -535,514 | -641,084 | 296,357 |
Net Income | -506,984 | -557,517 | -644,085 | 313,882 |
Net Change In Cash | 249,380 | 204,036 | 180,080 | 793,735 |
Cost of Revenue | -90,008 | -473,797 | 570,545 | |
Free Cash Flow | -452,909 | -511,196 | -559,894 | 383,876 |
Cash | 71,286 | 119,709 | 209,948 | 684,636 |
Basic Shares | 60,558 | 59,642 | 58,518 | 56,168 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.89 |
2024-06-30 | -$0.80 |
2024-03-31 | $1.40 |
2023-12-31 | -$1.82 |
